Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. A growing body ...

Amsterdam, July 22, 2024 – To date Parkinson's disease (PD) is diagnosed clinically and rather late in the course of the disease. There is an urgent need to find an objective, quantifiable biomarker ...

In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...

Professor, Aarhus University, Dept. of Biomedicine (West), Director, DANDRITE, Danish Research Institute of Translational Neuroscience, (Nordic EMBL partnership for Molecular Medicine). Co-founder and ...

Skin biopsies detected phosphorylated alpha-synuclein in a high proportion of people with Parkinson's disease and other synucleinopathies. Finding a reliable diagnostic biomarker for synucleinopathies ...

“These are the first data to link ASC speck assembly, NLRP1 inflammasome activation, and alpha-synuclein aggregation in neurons of Parkinson’s disease patients,” said Stephen C. Glover, ZyVersa’s ...

Longitudinal skin biopsies of phosphorylated alpha-synuclein help differentiate mild cognitive impairment subtypes and track ...

A novel strategy that combines computational and experimental approaches has allowed researchers at Baylor College of Medicine and the Duncan Neurological Research Institute (Duncan NRI) at Texas ...

Parkinson’s disease is associated with the buildup of a particular brain protein that currently has no approved therapies addressing it. Novartis was among the companies pursuing this target, but its ...

– The sunbird αSyn™ assay accurately classified Parkinson’s disease-positive blood samples with 81% accuracy through the direct detection of EV-bound aggregated alpha-synuclein proteins – – With no ...